Transcatheter Mitral Valve Replacement for Severe Mitral Regurgitation: A Global Study

Transcatheter Mitral Valve Replacement for Severe Mitral RegurgitationSymptomatic mitral regurgitation is associated with high morbidity and mortality that can be alleviated partly by surgical mitral valve replacement. However, many patients do not undergo surgery. Transcatheter mitral valve replacement is an appealing option for this selected patient group.

 

This study aimed to examine the effectiveness and safety of transcatheter mitral valve replacement in a cohort of patients with native valve mitral regurgitation and high surgical risk.

 

Patients undergoing transapical transcatheter mitral valve replacement with a self-expanding prosthesis were prospectively enrolled and their short-term (30-day) outcomes were assessed.

 

Thirty high-surgical-risk patients (STS predicted risk of mortality score of 7.6 ± 5.7%) with grade 3 or 4 mitral regurgitation received the device, and there was successful implantation in 28 of them (93.3%).

 

There were no deaths, strokes, or peri-procedural infarctions. One patient died at 13 days from a hospital-acquired infection. One patient presented leaflet thrombosis that was resolved by increasing the range of anticoagulation with warfarin.

 

At 30 days, an echocardiography showed mild regurgitation in 1 patient, and absolutely none in the remaining 26 patients. There was also a significant reduction in the left ventricular end-diastolic and end-systolic volume indexes.

 

Seventy-five percent of the patients reported mild or no symptoms at follow-up.

 

Successful device implantation free of mortality, stroke, and prosthesis malfunction was 86.6%.

 

Conclusion

Transcatheter mitral valve replacement is an effective and safe therapy for selected patients with severe mitral regurgitation and high surgical risk.

 

Original title: Transcatheter Mitral Valve Replacement for Patients with Symptomatic Mitral Regurgitation. A Global Feasibility Trial.

Reference: David W.M. Muller et al. J Am Coll Cardiol. 2016 Dec 20. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...